医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

China Hepatitis C Virus Market Analysed & Forecast in Topical GlobalData Report Published at MarketPublishers.com

2013年06月13日 PM11:40
このエントリーをはてなブックマークに追加


 

LONDON

As no effective vaccine against the hepatitis C virus (HCV) has been discovered so far, the market is driven by therapeutics. Additionally, an increased awareness of the disease and China’s tendency to treat HCV once it is diagnosed are anticipated to be the key drivers of market growth during the forecast period.

Standard interferon drugs are currently leading the market in China. Merck’s Intron A (interferon alfa-2b) is the most typically prescribed standard interferon in the country, though Roferon-A (interferon alfa-2a) and Kadmon’s Infergen (interferon alfacon-1) are used often as well. The entrance of next-generation HCV therapies is expected to radically alter the HCV treatment algorithm. Interferon-free regimens are likely to become increasingly popular due to their more tolerable side-effect profiles and decreased duration of therapy as against the current standard of medical care.

Topical research report “PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis” created by GlobalData provides an all-encompassing analysis of the HCV market in China.

The study gives a detailed overview of the disease including epidemiology, etiology and symptoms; offers diagnosis, pathology and treatment guidelines; and examines the changing competitive landscape for HCV. The report presents insightful information on the key drugs in the country including product description, safety and efficacy profiles and a SWOT analysis; offers sales forecast for the top drugs in China from 2012-2022. In-depth analysis of the impact of major events as well as of the key drivers and restraints affecting the HCV market is included, too.

Report Details:

Title: PharmaPoint: Hepatitis C Virus – China Drug Forecast and Market Analysis

Published: May, 2013

Pages: 102

Price: US$ 4,995.00

http://marketpublishers.com/report/life_sciences/pharmaceuticals/pharmapoint-hepatitis-c-virus-china-drug-forecast-n-market-analysis.html

More Topical GlobalData Reports Include:

More topical reports by GlobalData can be found at http://marketpublishers.com/members/global_data/info.html

CONTACT

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide
  • Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  • Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
  • オクタファルマ・グループが2018年の好業績を発表
  • 香港贸发局香港国际医疗及保健展尖端医疗科技及保健产品 迎合采购所需